Physician profile
Saurav Chatterjee
NPI 1295963072
$33,482.84
in general payments reported to CMS, 2019-2025
14 companies · $48.40 in 2025
The $48.40 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $113 · 2021: $40.00 · 2022: $13K · 2023: $20K · 2024: $71.61 · 2025: $48.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $345 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,500.00 |
| Food and Beverage | $345.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27,164.45 | 2019-2023 | Jeti Peripheral Catheter, Mediguide, Jeti |
| Teleflex LLC | $5,303.97 | 2022-2025 | Chocolate |
| Medtronic, INC. | $234.36 | 2021-2024 | Symplicity G3, Onyx Frontier |
| Medtronic Vascular, INC. | $179.89 | 2019 | |
| Abiomed | $175.00 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $138.24 | 2020-2022 | |
| Becton, Dickinson and Company | $70.00 | 2024-2025 | Bd Introsyte, Introducer Needle |
| Janssen Pharmaceuticals, INC | $68.25 | 2023 | Xarelto |
| Teleflex Medical Incorporated | $38.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.41 | 2022-2023 | Camzyos |
| Amgen INC. | $22.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.38 | 2019 | |
| Pfizer INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurav Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.